Pancreatic cancer screening in patients with presumed branch-duct intraductal papillary mucinous neoplasms

Table 2 Frequency of concomitant pancreatic ductal adenocarcinoma in patients with branch-duct - intraductal papillary mucinous neoplasm during follow-up

Article	Country	Design	n	Diameter of IPMN in mm*	Follow-up inmo*	Surveillanceinterval	Imaging(optional imaging)	Incidence of concomitant PDAC,n (%)
Kobayashi et al[31], 2005	Japan	Retrospective	47	28.2	41.0	No description	EUS	3 (6.4)
Tada et al[32], 2006	Japan	Prospective	80	22.0	48.0	q6 mo	US, CT, MRI, EUS	2 (2.5)
Uehara et al[7], 2008	Japan	Retrospective	60	No description	87.0	q3-6 mo	US (CT, MRI, EUS)	5 (8.3)
Sawai et al[33], 2010	Japan	Retrospective	103	18.0	59.0	At least yearly	EUS	2 (1.9)
Tanno et al[8], 2010	Japan	Prospective	89	20.0	64.0	q6-12 mo	CT, MRI, EUS	4 (4.5)
Maguchi et al[9], 2011	Japan	Retrospective	349	19.0	44.0	No description	US, CT, MRI, EUS, ERCP	7 (2.0)
Ohno et al[34], 2012	Japan	Retrospective	142	22.3	42.5	q6 mo	CE-EUS, CT	5 (3.5)
Sahora et al[35], 2013	United States	Retrospective	411	16.0	60.0	q3-24 mo	CT, MRI	3 (0.7)
Kamata et al[36], 2014	Japan	Retrospective	102	No description	42.0	q3 mo	US, CT, MRI, EUS	7 (6.9)
Malleo et al[37], 2015	Italy	Prospective	569	18.0	56.0	At least yearly	MRI (EUS)	3 (0.5)

*Mean, or, if not available, median or midpoint of range. CT: Computed tomography; EUS: Endoscopic ultrasonography; MRI: Magnetic resonance imaging; PDAC: Pancreatic ductal adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasm; US: Ultrasonography.